Short Interest in Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) Decreases By 33.7%

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) saw a significant decline in short interest in the month of December. As of December 31st, there was short interest totaling 25,945 shares, a decline of 33.7% from the December 15th total of 39,109 shares. Currently, 2.7% of the company’s shares are short sold. Based on an average daily volume of 34,460 shares, the short-interest ratio is presently 0.8 days. Based on an average daily volume of 34,460 shares, the short-interest ratio is presently 0.8 days. Currently, 2.7% of the company’s shares are short sold.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on SNSE. Wall Street Zen raised shares of Sensei Biotherapeutics to a “hold” rating in a research note on Saturday, December 27th. Weiss Ratings reissued a “sell (d-)” rating on shares of Sensei Biotherapeutics in a research report on Monday, December 29th. Finally, HC Wainwright downgraded Sensei Biotherapeutics from a “buy” rating to a “neutral” rating in a research note on Thursday, October 30th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Sensei Biotherapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $55.00.

Sensei Biotherapeutics Stock Down 10.1%

NASDAQ:SNSE opened at $10.44 on Friday. The company’s 50 day moving average is $9.41 and its 200-day moving average is $9.14. Sensei Biotherapeutics has a 12 month low of $5.00 and a 12 month high of $18.35. The firm has a market cap of $13.15 million, a price-to-earnings ratio of -0.55 and a beta of 0.28.

Sensei Biotherapeutics (NASDAQ:SNSE) last announced its earnings results on Friday, November 14th. The company reported ($3.62) EPS for the quarter, topping the consensus estimate of ($4.11) by $0.49. Research analysts predict that Sensei Biotherapeutics will post -1.17 EPS for the current fiscal year.

Insider Activity

In related news, major shareholder James Peyer sold 3,507 shares of the stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $7.96, for a total value of $27,915.72. Following the completion of the transaction, the insider owned 155,142 shares in the company, valued at $1,234,930.32. This trade represents a 2.21% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders sold 27,907 shares of company stock worth $287,280 over the last quarter. 23.20% of the stock is owned by insiders.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.